Emerging treatments
Brilacidin
Brilacidin, a member of a novel class of antibiotics called defensin-mimetics, is in phase 3 testing for skin and skin-structure infection.
Delafloxacin
Delafloxacin is a fluoroquinolone antibiotic that is approved for the treatment of acute bacterial skin and skin-structure infections caused by designated susceptible bacteria.